<?xml version="1.0" encoding="UTF-8"?>
<p id="Par40">Eligible patients will be randomly assigned to the AS or XELOX group at a ratio of 1:1. The AS group will receive nab-paclitaxel plus S-1, and the XELOX group will receive oxaliplatin plus capecitabine (TableÂ 
 <xref rid="Tab1" ref-type="table">1</xref>). Randomization will be performed using an interactive speech/network response system, and patients will be stratified by histological differentiation type (differentiated vs. undifferentiated) and tumor stage (IIIA vs. IIIB, IIIC). This study is an open study. 
</p>
